KF
ALLO icon

Krilogy Financial’s Allogene Therapeutics ALLO Stock Holding History

Krilogy Financial’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.8K Buy
+16,780
New +$33.6K ﹤0.01% 955

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Krilogy Financial's ALLO Position: Q1 2026 in Review

Krilogy Financial opened a new position in Allogene Therapeutics (ALLO) in Q1 2026: 16,780 shares worth $39.8K. The stake represents ﹤0.01% of the portfolio and ranks #955 among its holdings.

208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Krilogy Financial held 16,780 shares of Allogene Therapeutics worth $39.8K as of Q1 2026.
  • Allogene Therapeutics was a new Krilogy Financial position in Q1 2026.
  • Allogene Therapeutics made up ﹤0.01% of Krilogy Financial's portfolio in Q1 2026, its #955 holding.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Krilogy Financial's 13F filing for Q1 2026, filed 17 Apr 2026.